Clinical Trial

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Study acronym: SOLSTICE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2019-03-08; most recent amendment 2025-12-15.
Status change: Completed → Active, Not Recruiting 2023-10-10
Status change: Active, Not Recruiting → Completed 2022-12-02
Status change: Recruiting → Active, Not Recruiting 2020-09-28
Status change: Not Yet Recruiting → Recruiting 2019-05-22
Trial Details
NCT Number NCT03869892
Lead Sponsor Institut de Recherches Internationales Servier
Collaborators: ADIR, a Servier Group company
Conditions Metastatic Colorectal Cancer
Enrollment 856 participants
Start Date 2019-03-21
Primary Completion 2021-06-29 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-22